Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2009

View Archived Issues

EMD-121974 combined with chemoradiotherapy may improve survival in cancer patients

Subretinal gene delivery of adeno-viral RPE65 is safe and effective in retinal degeneration patients

University of Maryland and Mitsubishi Tanabe Pharma claim KAT II inhibitors for AD

Boehringer Ingelheim discloses cannabinoid CB2 receptor agonists as analgesics

New Parkinson's disease clinical trial results reported at Movement Disorder Society meeting

HIV reverse transcriptase inhibitors in early development at Merck & Co.

Bayer Schering Pharma patents describe novel prostanoid IP receptor agonists

Novartis discloses CSF-1R inhibitors for the treatment of cancer

Efficacy and favorable safety of CCX282-B shown in induction of response phase of PROTECT-1 trial

BioMarin reports results from phase I PEG-PAL in phenylketonuria

Talecris receives orphan drug designation for human plasmin

ViroMed completes dosing in phase I trial for VM-202 in cardiovascular disease

FDA issues 74-day letter with respect to SkyePharma's NDA for asthma drug Flutiform

CHMP recommends granting of marketing authorization for Orphan Europe's Vedrop

FDA cleares Morphotek's IND to study MORAb-004 in solid tumors

Amarin reports results from phase IIa EN-101 trial in myasthenia gravis

FDA accepts for filing MonoSol's NDA for ondansetron orally dissolving film strip

Genmab completes recruitment in zalutumumab head and neck cancer study

GenPhar prepares tetravalent dengue vaccine for phase I clinical trials

Kamada reports positive proof-of-concept data for inhaled alpha-1 antitrypsin

NeurogesX provides FDA regulatory update for Qutenza

Delcath enrolls 75% of subjects in phase III clinical trial of PHP in melanoma

Istradefylline reduces off time in Parkinson's disease patients with motor complications

AS-1907417 shows preclinical potential for the treatment of type 2 diabetes

CIS-565C improves glucose metabolism with fewer CNS side effects in mouse models of obesity

Bayhill and Genentech sign worldwide license agreement for BHT-3021 in type 1 diabetes

Collegium submits SPA to FDA for phase III pivotal trial of tamper-resistant opioid COL-003